Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Epidemiology

Pathology

Internal Medicine

Surgery

Show all topics

DOI

10.1016/s0140-6736(17)30570-6

Other Formats

PDF